Drug-Linker Conjugates for ADC
Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.
The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.
ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.
Drug-Linker Conjugates for ADC Isoform Specific Products
-
Drug-Linker Conjugates for ADC
(327)
View all products
-
Auristatin
(45)
View all products
-
Camptothecins
(33)
View all products
-
Daunorubicins/
Doxorubicins (5)View all products
-
Duocarmycins
(8)
View all products
-
Maytansinoids
(19)
View all products
-
Pyrrolobenzodiazepines
(5)
View all products
-
Traditional Cytotoxic Agents
(31)
View all products
-
Dual payloads
(5)
View all products
All Product Categories
-
Drug-Linker Conjugates for ADC Related Products (500)
Related Products (500)
-
Drug-Linker Conjugates for ADC Isoform Comparison
-
XMT-1519 conjugate-1 TFA
0 ImagesCat. No.: HY-148067AXMT-1519 conjugate-1 TFA (compound 31) is part of the drug-linker conjugate for ADC and can be conjugated with the HER-2 monoclonal antibody Calotatug (XMT-1519) (HY-P990909) for the synthesis of ADC.
-
N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
0 ImagesCat. No.: HY-177685N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
-
Mal-PEG4-Val-Cit-PAB-MSA-2
0 ImagesCat. No.: HY-181992Mal-PEG4-Val-Cit-PAB-MSA-2 is a Drug-Linker Conjugates for ADC. Mal-PEG4-Val-Cit-PAB-MSA-2 consists of the ADC Cytotoxin MSA-2 (HY-136927) and a linker Mal-PEG4-Val-Cit-PAB-OH (HY-140143). Mal-PEG4-Val-Cit-PAB-MSA-2 can be used for synthesis of ADCs.
-
Fmoc-Gly-Gly-Phe-Gly-Docetaxel
0 ImagesCat. No.: HY-181428CAS No.: 3061439-13-9Fmoc-Gly-Gly-Phe-Gly-Docetaxel (compound 16h-3) is a drug-linker conjugate for ADC, which comprises a microtubule depolymerization inhibitor and a linker. Puxitatug samrotecan drug-linker can be used to synthesize antibody-drug conjugate (ADC).
-
DBCO-PEG8-VKG-CPT2
0 ImagesCat. No.: HY-175272DBCO-PEG8-VKG-CPT2 is a drug-linker conjugate for ADC. DBCO-PEG8-VKG-CPT2 consists of a topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162) and a stable and cleavable linker (DBCO-PEG8-VKG) (HY-175426). DBCO-PEG8-VKG-CPT2 can be used for synthesis of ADCs.
-
Mal-VC-PAB-seco-CBI-PBD dimer
0 ImagesCat. No.: HY-185493CAS No.: 1661823-95-5Mal-VC-PAB-seco-CBI-PBD dimer is a highly active drug-linker conjugate. Mal-VC-PAB-seco-CBI-PBD dimer integrates the DNA-damaging effects of two distinct types of compounds: seco-cyclopropabenzindoline (seco-CBI) and pyrrolobenzodiazepine (PBD). Mal-VC-PAB-seco-CBI-PBD dimer is linked via a valine-alanine (VC) linker cleavable by cathepsin B and achieves targeted delivery relying on monoclonal antibodies. Mal-VC-PAB-seco-CBI-PBD dimer is applicable for cancer research.
-
HE-S2
0 ImagesCat. No.: HY-144497CAS No.: 2939851-67-7HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity.
-
Tesirine (GMP)
0 ImagesCat. No.: HY-128952GCAS No.: 1595275-62-9Synonyms: SG3249 (GMP)Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity.
-
Mal-Toxophore
0 ImagesCat. No.: HY-164705CAS No.: 2592504-91-9Mal-Toxophore is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164759).
-
Mal-PEG4-Val-Ala-Ph-2,2-dimethylpropanoic acid
0 ImagesCat. No.: HY-184906Mal-PEG4-Val-Ala-Ph-2,2-dimethylpropanoic acid is a maleimide-functionalized PEG4-Val-Ala dipeptide linker bearing a trimethyl-locked adapter for exatecan conjugation, which enables thiol conjugation via the maleimide group and facilitates payload release. Mal-PEG4-Val-Ala-Ph-2,2-dimethylpropanoic acid is used in cancer research.
-
N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
0 ImagesCat. No.: HY-177679N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
-
MC-Sq-Cit-PAB-Dolastatin10
0 ImagesCat. No.: HY-128894CAS No.: 1941168-65-5MC-Sq-Cit-PAB-Dolastatin10 is a agent-linker conjugate for ADC with potent antitumor activity by using Dolastatin10 (a tubulin polymerization inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
-
ST8154AA1
0 ImagesCat. No.: HY-112805CAS No.: 2247025-59-6ST8154AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.
-
Asn-Pro-Val-PABC-MMAE TFA
0 ImagesCat. No.: HY-144629CAS No.: 2893871-67-3Asn-Pro-Val-PABC-MMAE TFA (compound 8) is a potent ADC Linker used in the synthesis of antibody-drug conjugates (ADCs).
-
BrAc-Galactose-Sar-N-Me-alanine-DM1
0 ImagesCat. No.: HY-167960CAS No.: 3023560-93-9BrAc-Galactose-Sar-N-Me-alanine-DM1 (compound 11) is a drug-linker conjugate for ADC, which can be conjugated with the anti-TM4SF1 antibody (e.g., AGX-A07 (HY-P991187) for the synthesis of ADC.
-
BL20-MMAE
0 ImagesCat. No.: HY-177109CAS No.: 2765612-38-0BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE (HY-15162) via a BL20 linker.
-
MMAE-PAB(p-glucuronide)-PEG3-aminooxy
0 ImagesCat. No.: HY-153642CAS No.: 1835250-20-8MMAE-PAB(p-glucuronide)-PEG3-aminooxy is a compound with potential drug delivery.
-
CL2E-SN38
0 ImagesCat. No.: HY-139909CAS No.: 1639139-65-3CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.
-
Mal-Val-Lys-PAB-CBI-PBD dimer
0 ImagesCat. No.: HY-185494CAS No.: 1661824-39-0Mal-Val-Lys-PAB-CBI-PBD dimer is a Drug-Linker Conjugates for ADC. Mal-Val-Lys-PAB-CBI-PBD dimer consists of the ADC Cytotoxin CBI-PBD dimer and a linker Mal-Val-Lys-PAB. Mal-Val-Lys-PAB-CBI-PBD dimer exhibits alkylating activity at A-T-rich DNA minor groove adenine residues, disrupting DNA integrity. Mal-Val-Lys-PAB-CBI-PBD dimer induces cancer cell growth inhibition and cellular death. Mal-Val-Lys-PAB-CBI-PBD dimer can be used for the research of cancer.
